NYSEHealth CareOrthopedic, Prosthetic & Surgical Appliances & SuppliesOR AKIVA, Israel

Regentis Biomaterials Ltd. RGNT

Ask your AI

Estimated market cap $6.37M5.18M shares, shares as of Dec 31, 2025CIK 1912966

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

1 added · 2 trimmed

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

IPO prospectus

Updated

Regentis Biomaterials Ltd.’s initial public offering: where it stands and what the registration statement says.

Updated · Proposed ticker RGNT, NYSE American · First filed Mar 11, 2025

Read from the F-1/A filed Oct 24, 2025 · Read it on sec.gov ↗

Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.

AI summary of the prospectus. Written by AI from the parts of the prospectus listed in the filing, and checked against its text. This is information, not investment advice.

All filings of this IPO Read the F-1/A on sec.gov ↗

IPO prospectus

Regentis Biomaterials Ltd.’s initial public offering: where it stands and what the registration statement says.

Loading…

Latest 10-Q

What changed in Regentis Biomaterials Ltd.'s latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

103,012 shares

3 funds report RGNT. Values checked against market prices.

Funds own 16% of shares (Q2 2026)

6 funds hold the stock.

Q3 2026: 2.0% · 5,560 of ~8,900 funds reported so far

Q4 20255.4%
Q1 202611%
Q2 202616%
Q3 2026 (so far)2.0%

Q3 2026. 0 new, 1 added to, 2 trimmed, 3 exited since Q2 2026.

Top 13F holders
#
1	Warberg Asset Management LLC 13F ↗	58,526	$108.9K	-32.7%
2	Jane Street Group, LLC 13F ↗	43,240	$78.3K	-0.2%
3	UBS Group AG 13F ↗	1,246	$2,256	+187.1%

Download CSV Every fund that holds RGNT, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Regentis Biomaterials Ltd. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Regentis Biomaterials Ltd. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2025	3	—	281,015	$1.9M
Q1 2026	3	0	551,844	$1.7M
Q2 2026	6	+3	845,791	$3.0M
Q3 2026	3	-3	103,012	$189.4K

Each point is a quarter-end, from Q4 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (M8211G108). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes2 in 12 mo 8-K eventsNone in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials0 active IPO history4 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: REGENTIS BIOMATERIALS LTD.
Address: 12 HA'ILAN STREET, NORTHERN INDUSTRIAL, ZONE, P.O. BOX 260, OR AKIVA, Israel
Phone: 30600
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, emerging growth company
Incorporated in: Israel
Listed as: RGNT (NYSE)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.23−$0.02 (−1.60%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $1.17 · High $1.63Nov 13, 2026

Aug 13, 2026Low $1.17 · High $2.23Nov 13, 2026

Dec 4, 2025Low $1.17 · High $9.40Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.